Chen XY, et al. - Researchers investigated the correlation between the development of acute kidney injury (AKI) and the combined use of vancomycin (VAN) and piperacillin/tazobactam (PT) by analyzing data from eight observational cohort studies (a total of 10727 participants received VAN and PT vs VAN and other β-lactams) identified from PubMed, Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI) Database, Wan Fang Digital Periodicals Database (WFDP), and China Science Citation Database (CSCD). Data showed a correlation between the development of AKI and concurrent use of VAN and PT vs concomitant VAN and β-lactams. Studies comparing concurrent VAN and PT use with concurrent VAN and β-lactam (cefepime) use also showed similar results. Overall, with respect to β-lactam therapy in clinical practice, taking into account an elevated risk of AKI due to the combined use of VAN and PT was recommended.